Form 4: Dynavax Technologies SVP and CMO, Robert Janssen, Reports Transactions in Company Stock

Robert Janssen, SVP and CMO of Dynavax Technologies, reports the acquisition and disposal of Dynavax stock and derivative securities on February 13, 2025.

Summary

• On February 13, 2025, Robert Janssen, SVP and CMO of Dynavax Technologies, reported transactions involving Dynavax common stock and derivative securities.
• Janssen acquired 13,000 shares of common stock through the vesting of restricted stock units (RSUs).
• He also disposed of 4,614 shares to satisfy tax withholding requirements related to the RSU vesting at a price of $12.69.
• Following these transactions, Janssen directly owns 69,622 shares of Dynavax common stock.
• Janssen was also granted 55,000 stock options with an exercise price of $12.69, vesting over three years, and 33,333 RSUs vesting over three years.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects routine transactions related to executive compensation. The vesting of RSUs suggests the achievement of performance goals, which is mildly positive.

Positives

• The vesting of RSUs indicates that performance conditions were met, which could be viewed positively.

Negatives

• The disposal of shares to cover tax obligations could be seen as a minor negative, although it's a common practice.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options and RSUs suggests continued involvement and alignment with the company's long-term performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the biotechnology industry, used to incentivize and retain key personnel.
• Vesting schedules of three years are typical for such grants, aligning with industry norms.
• The size of the grants is relative to the position of the reporting person within the company and is consistent with standard compensation packages for SVPs and CMOs in comparable biotech firms.

Stakeholder Impact

• The transactions have a minor impact on shareholders, providing transparency into executive compensation and ownership.
• Employees may be indirectly affected by the vesting of RSUs, as it reflects the achievement of company performance goals.

Key Dates